- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00608465
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
July 13, 2017 updated by: James Muldowney, Vanderbilt University
The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women.
It can also lead to the early development of hardening of the arteries and increased risk of a stroke.
This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Obesity is an increasingly important risk factor for cardiovascular disease in men and women and is associated with the premature development of atherosclerosis, and increased risk of stroke.
A classical perspective of cardiovascular risk does not adequately explain all of the cardiovascular events associated with obesity.
Elevated plasma levels of plasminogen activator inhibitor type I (PAI-1) are one of the biochemical hallmarks for obesity and likely contribute the increased risk of atherothrombotic events in patients with obesity.
The central hypothesis of this proposal is that the increased risk of atherothrombotic events in patients with obesity.
The central hypothesis of this proposal is that vascular PAI-1 excess promotes the development of intravascular thrombosis.
We will test the hypothesis that secreted factors from adipocytes have autocrine, paracrine and endocrine effects that have a deleterious effect on the fibrinolytic system, either by enhancing PAI-1 production or impairing endothelial t-PA release.
From a public health perspective, there is no greater threat to America's cardiovascular health than the epidemic of obesity.
It is anticipated that this study will provide new insights nto the molecular mechanisms that contribute to the development of fibrinolytic dysfunction and cardiovascular disease in obesity.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or females between the ages of 18 to 65 years of age.
- Documented diagnosis for the metabolic syndrome:
- Subjects with hypertension (SP>130mmHg)
- Subjects with central obesity (females waist >35"; males waist >40")
- Subjects with dyslipidemia (HDL <40mg/dl, triglycerides > 150 mg/dl)
- Subjects who are insulin resistance (fasting glucose >100mg/dl)
Exclusion Criteria:
- Subjects who smoke
- Women who are pregnant (confirmed by urine beta-HCG).
- Women who are breast feeding
Subjects with documentation of the following health risk:
- Subjects with serum creatinine >2.0 mg/dl (males), >1.8 mg/dl (females)
- Subjects whose creatinine clearance < 50 mls/min
- Subjects with serum potassium >5.5mEql
- Subjects with Type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration >0.2)
- Subjects who are currently taking the following medications:
- Warfarin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment A
Eplerenone (study drug)
|
5 mg x 1 week followed by 10 mg x 9 weeks.
Other Names:
|
Active Comparator: Treatment B
Ramipril
|
Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secreted Factors From Adipocytes Have Autocrine, Paracrine and Endocrine Effects That Have a Deleterious Effect on the Fibrinolytic System, Either by Enhancing PAI-1 Production or Impairing Endothelial t-PA Release
Time Frame: 10-Week period
|
10-Week period
|
This Study Will Analyze Patients' Genetic Make up to Identify Who May be at Greater Risk for Heart Disease and Strokes in Relationship to High Blood Pressure and Central Obesity.
Time Frame: 10-weeks
|
10-weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: James AS Muldowney, MD, Vanderbilt University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2006
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
January 22, 2008
First Submitted That Met QC Criteria
February 5, 2008
First Posted (Estimate)
February 6, 2008
Study Record Updates
Last Update Posted (Actual)
August 11, 2017
Last Update Submitted That Met QC Criteria
July 13, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Insulin Resistance
- Hyperinsulinism
- Obesity
- Metabolic Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Ramipril
- Eplerenone
Other Study ID Numbers
- 060369
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome X
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Universidad de los Andes, ChileCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Federal University of São PauloCompletedPhysical Activity | Endothelial Dysfunction | Metabolic Syndrome xBrazil
-
Midwest Biomedical Research FoundationSuspended
-
Instituto de Seguridad y Servicios Sociales de...Enrolling by invitationCardiovascular Diseases | Mediterranean Diet | Metabolic Syndrome xMexico
-
Wake Forest University Health SciencesBrigham and Women's HospitalCompletedDiabetes | Metabolic Syndrome xUnited States
-
University of PennsylvaniaAbbottCompletedMetabolic Syndrome xUnited States
-
Queen Margaret UniversityUnknownCardiovascular Diseases | Metabolic Syndrome XUnited Kingdom
-
Arne AstrupUniversity of Aarhus; University Hospital, Gentofte, Copenhagen; Technical University...CompletedMetabolic Syndrome XDenmark
Clinical Trials on Eplerenone
-
Tufts Medical CenterCompleted
-
Vanderbilt University Medical CenterNational Center for Research Resources (NCRR)Completed
-
Darnitsa Pharmaceutical CompanyACDIMA BiocenterCompletedHealthy Subjects | BioequivalenceJordan
-
Pr. Nicolas GIRERDRecruitingKidney Transplantation for More Than One Year | Patients With a Kidney Transplantation on CyclosporineFrance
-
University of CincinnatiWithdrawnLow Back Pain | Sciatic Radiculopathy | Degenerative Intervertebral DiscsUnited States
-
Subha RamanBallou SkiesCompletedDuchenne Muscular DystrophyUnited States
-
Semmelweis UniversityCompletedChronic Central Serous ChorioretinopathyHungary
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHealthy VolunteersUnited States
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)WithdrawnHypertensionUnited States